Ireland
--:--IST
Active, not recruiting Phase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471 · tracked via the Priya Life Science Mexico tracker
Phase
Phase 3
Started
2025-09-15
Last updated
2026-10-02

Condition(s) studied

Osteoarthritis

Investigational drug(s) / intervention(s)

Orforglipron →Placebo

Orforglipron: Administered orally

Placebo: Administered orally

Study summary

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee Exclusion Criteria: * Have gained or lost more than 11 pounds within 90 days prior to screening * Have had a surgery for obesity or plan to have one in the next 18 months * Have an active knee infection * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure * Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening

Primary outcome measure(s)

  • Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score — Baseline, Week 72

Trial sites (88)

FacilityCityRegionStatus
Arizona Research Center Phoenix Arizona
AMR Clinical Tempe Arizona
Care Access - Huntington Beach Huntington Beach California
Care Access - Thousand Oaks Thousand Oaks California
Legacy Clinical Trials Colorado Springs Colorado
Chase Medical Research, LLC Waterbury Connecticut
Care Access - Decatur Decatur Georgia
North Georgia Clinical Research Woodstock Georgia
Northwestern University Chicago Illinois
AMR Clinical Newton Kansas
MedVadis Research Corporation Waltham Massachusetts
StudyMetrix Research City of Saint Peters Missouri
AMR Clinical Kansas City Missouri
Cardio Metabolic Institute Somerset New Jersey
Carolina Research Center Shelby North Carolina
University Orthopedics Center Altoona Pennsylvania
Care Access - Rapid City Rapid City South Dakota
AMR Clinical Knoxville Tennessee
Mercy Family Clinic Dallas Texas
Juno Research Houston Texas
Biopharma Informatic, LLC Houston Texas
Activian Clinical Research Kingwood Texas
Advanced Rheumatology of Houston - Woodlands The Woodlands Texas
Charlottesville Medical Research Charlottesville Virginia
Gershon Pain Specialists Virginia Beach Virginia
Northwest Clinical Research Center Bellevue Washington
Aggarwal and Associates Limited Brampton Canada
Diex Recherche Inc. Division Joliette Joliette Canada
Your Research Network Niagara Falls Canada
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc. Québec Canada
Alpha Recherche Clinique Québec Canada
ALPHA Recherche Clinique Québec Canada
Bluewater Clinical Research Group Inc. Sarnia Canada
Winterberry Research Inc. Stoney Creek Canada
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technolo -T Baotou China
Xuanwu Hospital Capital Medical University Beijing China
The Second Affiliated Hospital Chongqing Medical University Chongqing China
The Fourth Affiliated Hospital of Harbin Medical University Harbin China
The Second People's Hospital of Hefei Hefei China
Jinan Central Hospital Jinan China

+ 48 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07153471 on ClinicalTrials.gov ↗ ← All trials in Mexico